

# Major Products

## Innovative Drugs

Brand Name (Generic Name)	Efficacy	Launched	Remarks
Japan [Daiichi Sankyo Co., Ltd.]			
<i>Effient</i> ( <i>prasugrel</i> )	Antiplatelet agent	2014	Inhibits platelet aggregation and reduces the incidence of artery stenosis and occlusion.
<i>PRALIA</i> ( <i>denosumab</i> )	Treatment for osteoporosis	2013	Human monoclonal antibody that binds to RANKL. A subcutaneous injection for use once every six months as a novel treatment for osteoporosis.
<i>TENELIA</i> ( <i>teneligliptin</i> )	Type 2 diabetes mellitus treatment	2012	DPP-4 (dipeptidyl peptidase-4) inhibitor. Inhibits the activity of DPP-4, an enzyme that inactivates incretin, which is a glucose-dependent insulin-releasing hormone excreted from the gastrointestinal tract, and thereby increases incretin concentration in blood and facilitates insulin release.
<i>RANMARK</i> ( <i>denosumab</i> )	Treatment for bone complications caused by bone metastases from tumors	2012	Human monoclonal antibody that binds to RANKL. A new and effective treatment option for treating bone disorders stemming from multiple myeloma and bone metastases from solid tumors.
<i>LIXIANA</i> ( <i>edoxaban</i> )	Anticoagulant	2011	Orally administered Factor Xa inhibitor. It is an anticoagulant that specifically, reversibly, and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Approved for the prevention of venous thromboembolism (VTE) in patients with lower limb orthopedic surgery.
<i>LIXIANA</i> ( <i>edoxaban</i> )	Anticoagulant	2014	Approved for additional indications for the prevention of ischemic stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF) and for the treatment and recurrence prevention of venous thromboembolism (VTE) (deep vein thrombosis (DVT) and pulmonary thromboembolism).
<i>NEXIUM</i> ( <i>esomeprazole</i> )	Ulcer treatment	2011	Proton pump inhibitor. Licensed from AstraZeneca. It suppresses gastric acid secretion.
<i>Memary</i> ( <i>memantine</i> )	Alzheimer's disease treatment	2011	N-methyl-D-aspartate (NMDA) receptor antagonist. Memantine slows down progression of dementia symptoms in patients with moderate to severe Alzheimer's disease.
<i>Inavir</i> ( <i>laninamivir</i> )	Anti-influenza treatment	2010	Neuraminidase inhibitor that inhibits influenza viral proliferation. Treatment is completed with a single inhaled dosage.
<i>Urief</i> ( <i>silodosin</i> )	Treatment for dysuria	2006	Selective alpha 1A-adrenoceptor antagonist that selectively blocks alpha 1A-adrenoceptors in the lower part of the urinary tract. Compared with other alpha blockers, it causes fewer side effects, such as orthostatic hypotension.
<i>Olmetec</i> ( <i>olmesartan</i> )	Antihypertensive agent	2004	Angiotensin II receptor blocker. <i>Olmesartan</i> blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the angiotensin II receptor.
<i>Rezaltas</i> ( <i>olmesartan</i> )	Antihypertensive agent	2010	A combination of two antihypertensive drugs: calcium ion antagonist, <i>azelnidipine</i> , and an angiotensin II receptor blocker, <i>olmesartan medoxomil</i> .
<i>Cravit</i> ( <i>levofloxacin</i> )	Synthetic antibacterial agent	1993	New quinolone antibacterial agent offering strong antibacterial action and a broad antibacterial spectrum. Injectable preparation has been added as part of life-cycle management.
<i>Artist</i> ( <i>carvedilol</i> )	Treatment for hypertension, angina pectoris and chronic heart failure	1993	Beta blocker that selectively blocks beta-adrenaline receptors of the sympathetic nerve.
<i>Mevalotin</i> ( <i>pravastatin</i> )	Antihyperlipidemic agent	1989	HMG-CoA reductase inhibitor (statin) that lowers blood cholesterol levels by inhibiting cholesterol synthesis in the liver.
<i>Omnipaque</i> ( <i>iohexol</i> )	Contrast medium	1987	Nonionic contrast medium used to improve visibility of diagnostic X-ray imaging is inadequate.
<i>Loxonin</i> ( <i>loxoprofen</i> )	Anti-inflammatory analgesic	1986	Nonsteroidal anti-inflammatory analgesic. <i>Loxonin</i> tablets and granules have strong analgesic activity with lowered gastric side effects. <i>Loxoprofen</i> is a prodrug and is not metabolized in the stomach but activated after absorption through the small intestine. Other formulations such as tape are also available as a part of life-cycle management.



Olmetec (Japan)



NEXIUM (Japan)



PRALIA (Japan)



Effient (Japan)



LIXIANA (Japan)



Memary (Japan)



RANMARK (Japan)



TENELIA (Japan)

## Innovative Drugs

Brand Name (Generic Name)	Efficacy	Launched	Remarks
US [Daiichi Sankyo Inc.]			
<i>MOVANTIK</i> ( <i>naloxegol</i> )	Opioid-induced constipation treatment	2015	First once-daily oral product approved by the FDA for the treatment of opioid-induced constipation (OIC) for adults with chronic non-cancer pain.
<i>SAVAYSA</i> ( <i>edoxaban</i> )	Anticoagulant	2015	Orally administered Factor Xa inhibitor. It is an anticoagulant that specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Approved for indications to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF) and for the treatment of venous thromboembolism (VTE) (deep vein thrombosis (DVT) and pulmonary embolism (PE)).
<i>Effient</i> ( <i>prasugrel</i> )	Antiplatelet agent	2009	Inhibits platelet aggregation and reduces the incidence of artery stenosis and occlusion.
<i>Benicar</i>	Antihypertensive agent	2002	<i>Benicar</i> : <i>Olmesartan</i>
<i>Benicar HCT</i>	Antihypertensive agent	2003	<i>Benicar HCT</i> : Combination of <i>olmesartan medoxomil</i> and <i>hydrochlorothiazide</i> (diuretic)
<i>AZOR</i> ( <i>olmesartan</i> )	Antihypertensive agent	2007	<i>AZOR</i> : Combination of <i>olmesartan medoxomil</i> and <i>amlodipine besylate</i> (calcium channel blocker)
<i>TRIBENZOR</i>	Antihypertensive agent	2010	<i>TRIBENZOR</i> : Triple combination of <i>olmesartan medoxomil</i> , <i>hydrochlorothiazide</i> , and <i>amlodipine besylate</i>
<i>Welchol</i> ( <i>colesevelam</i> )	Hypercholesterolemia treatment / type 2 diabetes mellitus treatment	2000	Bile acid sequestrant. Marketed as a drug for treatment of hypercholesterolemia. Gained approval also for type 2 diabetes mellitus indication as part of life-cycle management.
US [Luitpold Pharmaceuticals, Inc.]			
<i>Injectafer</i> ( <i>ferric carboxymaltose injection</i> )	Anemia treatment	2013	Effective for patients who have intolerance to oral iron or who have had unsatisfactory response to oral iron or who have non-dialysis-dependent chronic kidney disease.
<i>Venofer</i> ( <i>iron sucrose injection</i> )	Anemia treatment	2000	Iron replacement product. Effective for treatment of iron deficiency anemia in dialysis patients.
Europe [Daiichi Sankyo Europe GmbH]			
<i>LIXIANA</i> ( <i>edoxaban</i> )	Anticoagulant	2015	Orally administered Factor Xa inhibitor. It is an anticoagulant that specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Approved for indications for the prevention of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF) and for the treatment and prevention of recurrent venous thromboembolism (VTE) (deep vein thrombosis (DVT) and pulmonary embolism (PE)).
<i>Effient</i> ( <i>prasugrel</i> )	Antiplatelet agent	2009	Inhibits platelet aggregation and reduces the incidence of artery stenosis and occlusion.
<i>Olmetec</i>	Antihypertensive agent	2002	<i>Olmetec</i> : <i>Olmesartan</i>
<i>Olmetec Plus</i>	Antihypertensive agent	2005	<i>Olmetec Plus</i> : Combination of <i>olmesartan medoxomil</i> and <i>hydrochlorothiazide</i> (diuretic)
<i>Sevikar</i> ( <i>olmesartan</i> )	Antihypertensive agent	2009	<i>Sevikar</i> : Combination of <i>olmesartan medoxomil</i> and <i>amlodipine besylate</i> (calcium channel blocker)
<i>Sevikar HCT</i>	Antihypertensive agent	2010	<i>Sevikar HCT</i> : Triple combination of <i>olmesartan medoxomil</i> , <i>hydrochlorothiazide</i> , and <i>amlodipine besylate</i>

## Generic Drugs

Brand Name (Efficacy)
Japan [Daiichi Sankyo Espha Co., Ltd.]
<i>levofloxacin</i> (Synthetic antibacterial agent)
<i>donepezil</i> (Alzheimer's disease treatment)
<i>telmisartan</i> (Antihypertensive agent)
<i>metformin</i> (Type 2 diabetes mellitus treatment)
<i>atorvastatin</i> (Antihyperlipidemic agent)

## OTC Related Drugs

Brand Name (Efficacy)
Japan [Daiichi Sankyo Healthcare Co., Ltd.]
<i>Lulu</i> (Combination cold remedy)
<i>Daiichi Sankyo Ichoyaku</i> (Multi-ingredient digestive remedy)
<i>Loxonin S</i> (Antipyretic analgesic)
<i>Patecs</i> (Antiphlogistic analgesic for external use)
<i>Transino</i> (Melasma treatment)

## Vaccines

Brand Name (Efficacy)
Japan [Kitasato Daiichi Sankyo Vaccine Co., Ltd., Japan Vaccine Co., Ltd.]
<i>ActHIB</i> (Haemophilus influenzae type b vaccine)
<i>Rotarix</i> (Rotavirus vaccine)
<i>Influenza HA Vaccine</i> (Seasonal influenza vaccine)
<i>Live Attenuated Measles / Rubella Combined Vaccine</i> (Measles and rubella vaccine)




MOVANTIK (US)



LIXIANA (Europe)



Loxonin S (OTC Related Drugs)



MINON series (OTC Related Drugs)



Injectafer (US)



levofloxacin (Generic Drugs)



Transino (OTC Related Drugs)



ActHIB (Vaccines)